ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Bioinformatics tools and experimental analysis combination for production of specific scFv against CD133.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Prominin-1, or CD133, is a membrane-bound pentaspan protein that has been utilized recently to identify cancer stem cells (CSCs) in a variety of carcinomas. Today, bioinformatics offers a potent tool for studying the structural and functional relationships of fusion proteins. A structure-activity relationship model based on physicochemical characteristics, biological functions of single-chain antibodies, and molecular conformation can be developed by the integration of biomolecular computer models with biological experiments. In the present study, a mice library of single-chain variable fragment (scFv) antibodies was developed by mRNA extracted from mice immunized for the efficient and specific identification of the N-terminal domain of recombinant CD133 (D-EC1). First, a part of sequences of the scFvs library were cloned in the T.vector and sequenced. Then, bioinformatics was used to select the scFvs with high affinity by molecular dynamics simulations and docking. Based on bioinformatics analysis, three scFvs were cloned and expressed. Finally, the ability of the selected scFv was confirmed with the indirect enzyme-linked immunosorbent assay (ELISA) and immunocytochemistry (ICC). ELISA data showed that scFv3 had a greater affinity for the N-terminal of recombinant CD133, and it was selected for the immunocytochemistry (ICC) analysis. The immunocytochemistry experiments confirmed that the obtained scFv could bind to the CD133-expressing HT-29 cells. Our results suggest that using bioinformatics tools could be applied as a new, rapid, and valid method for the design and development of antibodies with improved properties. The selected scFv may be successfully applied in scFv-based diagnostics and therapeutics.
Indexed as
Identifiers
40014126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.